DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

 

• DelveInsight’s Small Cell Lung Cancer Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer.

 

• The leading Small-cell Lung Cancer Companies include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen,  Cybrexa Therapeutics, and others.

 

• Promising Small-cell Lung Cancer pipeline therapies such as APG-1252, SYHA 1807, BNT 411, BMS 986012, LY 2510924, Serplulimab, Tiragolumab, Socazolimab, DS-7300, ABBV-011, HPN328, REQORSA, PEN-221, Gimatecan, LP002, LY01610, PLM60,  Ociperlimab, KRT-232, BI 764532, Nivatrotamab, CS1001, RRx-001, PF-06821497, CC-90011, AL3810, Lefitolimod, ALRN-6924,   CBX-12, and others 

 

• The Small Cell Lung Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.

 

To explore more information on the latest breakthroughs in the Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Small Cell Lung Cancer Pipeline Outlook

 

Small Cell Lung Cancer Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics.

 

Recent Developmental Activities in the Small Cell Lung Cancer Treatment Landscape

 

• In March 2022, Luye Pharma Group announced that it has filed a New Drug Application (NDA) in Hong Kong, China for Lurbinectedin, for the treatment of adult patients with metastatic Small-cell Lung Cancer (SCLC) with disease progression on or after receiving platinum-based chemotherapy. Lurbinectedin is an innovative oncology drug licensed to Luye Pharma by PharmaMar.

 

• In March 2022, Harpoon Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta-like ligand 3- (DLL3) targeting TriTAC®, for the treatment of Small-cell Lung Cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population.

 

• In March 2022, Akeso, Inc. announced that it has entered into a collaboration agreement with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L)1 inhibitor as first-line treatment.

 

• In March 2022, Shanghai Henlius Biotech, Inc., announced that the investigational new drug application (IND) of an international multicenter phase 3 studies of HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently developed by the Company, in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage Small-Cell Lung Cancer (LS-SCLC) has been approved by the National Medical Products Administration (NMPA). Previously, the global multi-center phase 3 study of HANSIZHUANG for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) has met the primary study endpoint of the overall survival (OS), and its NDA in China and MAA in the EU are expected to be filed in 2022, making HANSIZHUANG potentially the world’s first PD-1 inhibitor for the first-line treatment of SCLC.

 

• In January 2022, Genprex, Inc. announced that it has expanded its oncology research and development pipeline to include Small-cell Lung Cancer (SCLC) as an additional disease indication for its lead drug candidate, REQORSA™ Immunogene Therapy.

 

• In December 2021, Shanghai Henlius Biotech, Inc. announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC). There is no anti-PD-1 mAb approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) worldwide.

  

For further information, refer to the detailed Small Cell Lung Cancer Unmet Needs, Small Cell Lung Cancer Market Drivers, and Small Cell Lung Cancer Market Barriers, click here for Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

Small Cell Lung Cancer Emerging Drugs Profile

 

• AMG 757: Amgen

 

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

 

• APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

 

Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Small Cell Lung Cancer. The companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.

 

Request a sample and discover the recent advances in Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Small Cell Lung Cancer Treatment Landscape

 

Scope of the Small Cell Lung Cancer Pipeline Report

 

• Coverage- Global

 

• Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen,  Cybrexa Therapeutics, and others.

 

• Small-cell Lung Cancer pipeline therapies such as APG-1252, SYHA 1807, BNT 411, BMS 986012, LY 2510924, Serplulimab, Tiragolumab, Socazolimab, DS-7300, ABBV-011, HPN328, REQORSA, PEN-221, Gimatecan, LP002, LY01610, PLM60,  Ociperlimab, KRT-232, BI 764532, Nivatrotamab, CS1001, RRx-001, PF-06821497, CC-90011, AL3810, Lefitolimod, ALRN-6924,   CBX-12, and others

 

• Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Small Cell Lung Cancer Market Drivers and Small Cell Lung Cancer Market Barriers, click here @ Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Table of Content 

1. Introduction
2. Executive Summary
3. Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Pembrolizumab: Merck & Co
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Dostarlimab: GlaxoSmithKline
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AMG 757: Amgen
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. S 055746: Vernalis
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Small Cell Lung Cancer Key Companies
23. Small Cell Lung Cancer Key Products
24. Small Cell Lung Cancer- Unmet Needs
25. Small Cell Lung Cancer- Market Drivers and Barriers
26. Small Cell Lung Cancer- Future Perspectives and Conclusion
27. Small Cell Lung Cancer Analyst Views
28. Small Cell Lung Cancer Key Companies
29. Appendix

 

Got Queries? Find out the related information on Small Cell Lung Cancer Mergers and acquisitions, Small Cell Lung Cancer Licensing Activities @ Small Cell Lung Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/